The Benchmark Company
http://www.benchmarkcap.com/default.aspThe Benchmark Company, a full-service Broker Dealer, provides financial services to institutional and private clients. Its services include private placements, venture capital, M&A services, recapitalizations, divestitures & spin-offs, equity research as well as other financial services. The firm’s equity research division specializes in the media, energy, enterprise software, infrastructure software, and biotechnology & specialty pharmaceutical sectors.
-
BIOLASE, Inc. Announces Closing Of $14.4 Million Bought Offering
-
BIOLASE, Inc. Announces Pricing of $14.4 Million Bought Deal Offering
-
BIOLASE to Participate at the Benchmark Company Discovery One on One Investor Conference on November 18, 2020
-
BIOLASE Announces Closing Of Oversubscribed Rights Offering
-
BIOLASE Announces Expiration Of Oversubscribed Rights Offering
-
Biolase (BIOL) Announces Commencement of Rights Offering Subscription Period
-
BIOLASE, Inc. Announces Commencement of Rights Offering Subscription Period
-
BIOLASE, Inc. Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
-
BIOLASE, Inc. Announces Closing of $6.9 Million Registered Direct Offering Priced At-The-Market
-
Biolase (BIOL) Prices $6.9 Million Registered Direct Offering of Common Stock, Warrants
-
BIOLASE, Inc. Announces Pricing of $6.9 Million Registered Direct Offering Priced At-The-Market
-
Biolase (BIOL) Prices 7.82M Share Common Offering at $0.5750/Sh; Announces Concurrent Private Placement of Convertible Preferred Shares
-
BIOLASE Announces Pricing of $8.5 Million Public Offering of Common Stock and Concurrent Private Placement of Convertible Preferred Stock